PUBLISHER: QYResearch | PRODUCT CODE: 1874372
PUBLISHER: QYResearch | PRODUCT CODE: 1874372
The global market for Allergy Immunotherapy was estimated to be worth US$ 1785 million in 2024 and is forecast to a readjusted size of US$ 2805 million by 2031 with a CAGR of 7.0% during the forecast period 2025-2031.
This report provides a comprehensive assessment of recent tariff adjustments and international strategic countermeasures on Allergy Immunotherapy cross-border industrial footprints, capital allocation patterns, regional economic interdependencies, and supply chain reconfigurations.
Allergen immunotherapy, also known as desensitization or hypo-sensitization, is a medical treatment for some types of allergies. It is useful for environmental allergies, allergies to insect bites, and asthma. Its benefit for food allergies is unclear and thus not recommended. Immunotherapy involves exposing people to larger and larger amounts of allergen in an attempt to change the immune system's response. The primary therapeutic goals of allergy immunotherapy (AIT) include reducing symptoms, reducing symptomatic medication use, and improving allergyrelated quality of life. The evidence is strong that AIT achieves these goals and can alter the course of the disease, with benefits persisting in many patients for several years after treatment discontinuation.
The global allergy immunotherapy market is primarily driven by the rising prevalence of allergic conditions, such as allergic rhinitis, asthma, and food allergies, which affect hundreds of millions of individuals worldwide. Growing awareness about long-term treatment options and the effectiveness of immunotherapy in providing sustained symptom relief is increasing its adoption. Additionally, advancements in diagnostic techniques, improved formulations such as sublingual tablets, and support from regulatory authorities have facilitated market growth. The increasing demand for personalized medicine and a shift toward disease-modifying therapies are further propelling the market forward.
Despite its therapeutic potential, the allergy immunotherapy market faces several challenges. The long treatment duration-often lasting three to five years-can lead to poor patient compliance and high dropout rates. High upfront costs and limited reimbursement in some regions restrict accessibility for many patients. Moreover, the requirement for specialized healthcare infrastructure and trained professionals, especially for subcutaneous immunotherapy, limits adoption in low-resource settings. Safety concerns, including the risk of systemic allergic reactions, also hinder broader acceptance, particularly among pediatric and elderly populations. These barriers collectively slow market penetration and limit the therapy's full potential.
This report aims to provide a comprehensive presentation of the global market for Allergy Immunotherapy, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Allergy Immunotherapy by region & country, by Type, and by Application.
The Allergy Immunotherapy market size, estimations, and forecasts are provided in terms of sales volume (K Units) and sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Allergy Immunotherapy.
Market Segmentation
By Company
Segment by Type
Segment by Application
By Region
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size (value, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Allergy Immunotherapy manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Sales, revenue of Allergy Immunotherapy in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Sales, revenue of Allergy Immunotherapy in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.